#Foresight diagnostics trial
Patients’ tumor burden was evaluated by both CT imaging and ctDNA quantification via Foresight’s MRD assay from the start of the trial to the end of therapy. Non-responders received chemotherapy only.
#Foresight diagnostics plus
Responders, as assessed by CT imaging, continued on acalabrutinib plus chemotherapy. The open label trial is evaluating patients with newly diagnosed aggressive B-cell lymphoma and is designed such that patients first received the BTK inhibitor acalabrutinib for up to 14 days. In routine clinical care, using a tool like PhasED-Seq to study treatment response in real-time could enable physicians to direct management decisions earlier in the treatment process.” “This study found that changes in MRD levels may predict response to acalabrutinib treatment in as few as seven days and also suggested that ctDNA quantification by PhasED-Seq may demonstrate clinical response prior to CT scans in some cases. “Despite significant advances in how we treat patients with B-cell lymphomas, we still monitor disease burden and response to therapy primarily through CT imaging,” says Mark Roschewski, MD, Lymphoid Malignancies Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD., and principal investigator of the study. The study ( abstract #524) was described recently in a podium presentation at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition. Foresight Diagnostics in collaboration with the National Cancer Institute (NCI) announced results from an ongoing phase 2 clinical trial of the lymphoma drug acalabrutinib that included Foresight’s proprietary circulating tumor DNA (ctDNA) detection and minimum residual disease (MRD) monitoring assay, Phased variant Enrichment and Detection Sequencing (PhasED-Seq).ĭetection of ctDNA levels with PhasED-Seq was highly correlated with CT imaging and rapidly detected changes in tumor burden in newly diagnosed aggressive B-cell lymphoma patients treated with the drug.
0 kommentar(er)
